Video from Cambridge Biomedical’s Second Biannual Scientific Meeting – December 12, 2017

Cambridge Biomedical hosted its second annual scientific meeting this past December.  Forty scientists from the Greater Boston area attended the event focusing on the Microbiome.  It is Cambridge Biomedical’s pleasure with the approval of Synlogic to share Dr. Millet’s presentation. Once you have enjoyed the talk and would like to know how Cambridge Biomedical can contribute to your efforts please submit your request at https://www.cambridgebiomedical.com/contact-us.

“Synthetic Biotic™ Medicines: A New Class of Treatments.”

Dr. Yves Millet, Synlogic Therapeutics.

Abstract

The fields of synthetic biology and microbiome research have expanded greatly over the last decade enabling the development of new therapeutic strategies using engineered microbes that operate from within the gut. Synlogic is pioneering the development of a novel class of engineered, living drugs, called Synthetic Biotic™ Medicines, that can be designed to correct missing or dysfunctional metabolic activities or deliver effectors in the GI tract, with the potential to treat a wide range of diseases. The opportunities and challenges of this new therapeutic platform and the results obtained with two lead programs for the treatment of Urea Cycle Disorder and Phenylketonuria will be presented.

About Dr. Millet

Dr. Yves Millet is a Lead Scientist at Synlogic, located in Cambridge, MA, focused on the development of engineered probiotics for the treatment of rare metabolic disorders. Previously, he was a Scientist at Indigo (formerly known as Symbiota), a plant microbiome company based in Boston. Dr. Millet completed a Postdoctoral Fellowship in the laboratory of Dr. Matthew Waldor at Harvard Medical School where he studied the pathogenesis of Vibrio cholerae, the causative agent of cholera. He received his Ph.D. in Molecular and Cell Biology from Strasbourg University, France and carried out his graduate research in the laboratory of Prof. Frederick Ausubel at The Massachusetts General Hospital.

The development of cellular therapies could lead to advances in the treatment of trauma and critical care injuries

In recent years, significant advances have been made in treating those who have suffered severe hemorrhage and trauma, with the methods used to stop bleeding and resuscitate patients having made the largest strides. However, we currently provide little more than supportive care to those who survive the initial trauma. Since trauma is the leading cause of death for those aged 1 through 44, it is important that we develop therapeutic treatments for intermediate and long-term recovery.

An emerging area of particular interest in the treatment and rehabilitation of trauma survivors is the use of cellular therapy (CT), which can potentially be used to both prevent secondary injury and support the repair of injured tissues. Recent studies conducted with both animals and humans have shown that CT may be effective in treating conditions such as traumatic brain, spinal cord, and acute kidney injuries, organ failure, and burns, along with healing soft-tissue damage in the extremities.

Currently, there are two types of CT with significant potential for long-term healing. One is adult multipotent cells, which have the ability to replicate a limited number of differentiated cell types. The other type is pluripotent stem cells, which have an unlimited capacity for self-renewal and can also differentiate into any kind of cell in the body. Adult multipotent cells are more useful for the prevention of future injury and repair of injured tissues, whereas pluripotent cells are better suited for the replacement of cells in lost or injured tissue.

It’s evident that research involving CT could lead to a significant difference in how physicians care for patients healing from trauma, as well as how well these patients are able to return to a sense of normalcy after suffering from such extreme injuries.

For more information on the use of CT for trauma treatment, check out this article recently published in PlosMedicine.

By: Rebecca Yount

Meet and Greet the new VP of Scientific Affairs

Please join us to enjoy an informal breakfast welcoming Linda back to Boston. Meet Dr. Robbie and find out more about her vision to move Cambridge Biomedical into the next level of CRO/Sponsor partnerships. Share your needs and wishes directly to her, our top scientific executive. Take a look at her bio on our website and see how she is uniquely positioned to achieve this goal and provide drug development and medical diagnostic organizations superior support.

For full event details, see here!

RSVP to Eric Wexler:

Eric J. Wexler, M.B.A. Business Development Director - New England

Office: 617.456.0734 ~ Cell: 617.877.2489

ewexler@cambridgebiomedical.com